干旱区生态环境知识资源中心(Arid): Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial

Arid

DOI	10.1182/blood-2018-99-113777
	Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial
	Le Gouill, Steven 1,2; Morschhauser, Franck 3; Bouabdallah, Krimo 4; Cartron, Guillaume 5; Casasnovas, Rene-Olivier 6; Milpied, Noel-Jean 7; Gastinne, Thomas 8; Davies, Andrew John 9; Herbaux, Charles 10; Chiron, David 1,2; Callanan, Mary 11; Rule, Simon 12
来源期刊	BLOOD
ISSN	0006-4971
EISSN	1528-0020
出版年	2018
卷号	132
类型	Meeting Abstract
语种	英语
国家	France ; England
收录类别	SCI-E ; CPCI-S
WOS记录号	WOS:000454842803183
WOS类目	Hematology
WOS研究方向	Hematology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/208170
作者单位	1.Angers Univ, CRCINA, INSERM, CNRS, Nantes, France; 2.Nantes Univ, Nantes, France; 3.Hop Claude Huriez, CHRU Lille, Lille, France; 4.Univ Hosp Bordeaux, Hematol Clin, Pessac, France; 5.Univ Hosp Montpellier, Dept Clin Hematol, Montpellier, France; 6.Univ Hosp Dijon, Dept Hematol, Dijon, France; 7.Hop Haut Leveque Pessac, Pessac, France; 8.Nantes Univ Hosp, Clin Hematol, Nantes, France; 9.Univ Southampton, Canc Res UK Clin Ctr, Southampton, Hants, England; 10.CHU Lille, Serv Malad Sang, Lille, France; 11.Dijon Univ Hosp, Hematol Biol, Dijon, France; 12.Plymouth Univ, Dept Haematol, Sch Med, Plymouth, Devon, England
推荐引用方式 GB/T 7714	Le Gouill, Steven,Morschhauser, Franck,Bouabdallah, Krimo,et al. Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial[J],2018,132.
APA	Le Gouill, Steven.,Morschhauser, Franck.,Bouabdallah, Krimo.,Cartron, Guillaume.,Casasnovas, Rene-Olivier.,...&Rule, Simon.(2018).Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial.BLOOD,132.
MLA	Le Gouill, Steven,et al."Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial".BLOOD 132(2018).